Medicare coverage for a costly, but controversial, new Alzheimer’s drug will go only to people enrolled in approved clinical trials despite FDA endorsement of the medication.
Medicare limits payments for new Alzheimer’s drug to clinical trials
Medicare coverage for a costly, but controversial, new Alzheimer’s drug will go only to people enrolled in approved clinical trials despite FDA endorsement of the medication.